Radiation-Free Leukemia Treatment Options for Patients

Summary of the Article:⁤ Reduced-intensity⁢ Conditioning Regimen ‍Shows Promise in Transplant for AML

This article reports on a study presented at the ASH Annual Meeting and exposition (December 6-9, 2025) regarding a reduced-intensity conditioning ⁤(RIC) regimen for allogeneic hematopoietic stem cell transplant in patients with acute myeloid leukemia (AML).

Key Findings:

* High‍ Remission Rate: The‍ RIC regimen resulted in⁣ a 78% overall survival⁢ rate and a 71% event-free survival rate. A significant portion of patients (61%) were in second complete remission prior to transplant, and 40% had matched sibling donor transplants.
*⁤ GVHD Incidence: 39% of patients developed acute Graft-versus-Host Disease (GVHD), with most cases being mild to moderate (Grade 1/2). ⁢25% developed chronic GVHD, with most requiring systemic ⁣immunosuppressive treatment.
* Personalized Approach: Researchers are continuing to analyze data ‍to refine risk stratification and potentially⁣ further ⁣reduce the intensity of conditioning for certain patients, moving towards a more individualized treatment approach.
* Funding & Disclosures: The study was funded by‍ Gateway for‍ Cancer Research. Dr. Hisham Abdel-Azim, the lead researcher, has disclosed relationships with several pharmaceutical companies (Adaptive Biotech, Johnson & Johnson, kite Pharma, Novartis, and Vertex Pharmaceuticals).

overall Message:

The study suggests that a reduced-intensity conditioning regimen is a viable and ⁣effective option ‍for allogeneic ⁢stem cell ⁢transplant in AML ⁣patients, ⁣offering good survival rates and allowing for⁤ a more personalized treatment strategy based on individual patient risk factors.

Contact Information:

Hisham Abdel-Azim, MD, MS can be reached at habdelazim@llu.edu.

Source: Abdel-Azim H, et al.Abstract 163. Presented at: ASH Annual Meeting ⁤and ⁢Exposition; Dec. 6-9, ⁤2025; Orlando.